Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Published on by Research Hypothesis

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award

Dr. Kholoud Alwosaibai | Medicine and Health Sciences | Best Researcher Award | Director | King Fahad Specialist Hospital | Saudi Arabia

Dr. Kholoud Alwosaibai is a highly accomplished biomedical scientist, cancer geneticist, and immunotherapy specialist with over fifteen years of progressive experience in translational oncology, molecular medicine, and clinical genomics. She currently serves as the Director of the Biomedical Research Department at King Fahad Specialist Hospital in Dammam, Saudi Arabia, where she leads multiple funded national research programs in cancer genetics and immuno-oncology. Dr. Kholoud Alwosaibai earned her Ph.D. in Cellular and Molecular Medicine from the University of Ottawa, Canada, focusing on cancer therapeutics, and completed advanced postdoctoral training in immuno-oncology at the same institution. Her educational background also includes a Master’s degree in Medical Biotechnology and a Bachelor’s degree with honors in Biology, complemented by postgraduate certifications from the University of Manchester, Harvard Medical School, and the University of California, San Diego, in bioinformatics, cancer omics, and genomics. Professionally, Dr. Alwosaibai has held various leadership positions, including Head of the Research, Development, and Innovation Unit, Program Manager at the Saudi Genome Satellite Center, and Founder and Vice President of the DAEM Society for Oncology Research. Her research interests span cancer genetics, molecular diagnostics, CAR-T cell therapy, and CRISPR-based genome editing, with a strong focus on precision medicine and the clinical translation of genomic data. Dr. Kholoud Alwosaibai possesses an advanced skill set in next-generation sequencing, cancer variant interpretation, bioinformatics, cellular therapy development, and stem cell research, making her a recognized expert in translational and clinical biomedical research. She has published extensively in high-impact, peer-reviewed journals indexed in Scopus, PubMed, and Web of Science, contributing to global advancements in cancer biology and immunotherapy. Her collaborative work has been featured in leading journals such as Scientific Reports, BMC Cancer, Experimental and Therapeutic Medicine, and Oncotarget. Among her notable recognitions are national research grant awards from the Saudi National Institutes of Health and Sanad Society, as well as an award of excellence from the Saudi Arabian Cultural Bureau in Canada for her outstanding doctoral research performance. Throughout her career, Dr. Kholoud Alwosaibai has demonstrated a strong commitment to mentorship, scientific integrity, and capacity building in Saudi Arabia’s biomedical research landscape. Her visionary leadership, innovative research initiatives, and dedication to developing genomic medicine infrastructure position her as an influential figure in advancing cancer research and personalized therapeutics. In conclusion, Dr. Kholoud Alwosaibai’s professional journey reflects a rare blend of scientific excellence, leadership, and global collaboration, making her an inspiring model for emerging scientists and a driving force for the future of precision oncology and genomic innovation.

Profile: Scopus | ORCID

Featured Publications 

  1. Alwosaibai, K., Abedini, A., Al-Hujaily, E. M., Tang, Y., Garson, K., Collins, O., & Vanderhyden, B. C. (2017). PAX2 maintains the differentiation of oviductal epithelium and inhibits the transition to a stem cell-like state. Oncotarget. Citations: 85

  2. Gharaibeh, L., Elmadany, N., Alwosaibai, K., & Alshaer, W. (2020). Notch 1 in cancer therapy: Possible clinical implications and challenges. Molecular Pharmacology. Citations: 64

  3. Ghandorah, S., & Alwosaibai, K. (2021). Post-liver transplantation GVHD: Time to consider histocompatibility testing. Journal of Liver Transplantation. Citations: 22

  4. Alwosaibai, K., Al-Hujaily, E. M., Alamri, S., Ghandorah, S., Garson, K., & Vanderhyden, B. C. (2022). PAX2 induces vascular-like structures in normal ovarian cells and ovarian cancer. Experimental and Therapeutic Medicine, 23(6), 412. Citations: 37

  5. Alwosaibai, K., Aalmri, S., Mashhour, M., Ghandorah, S., Alshangiti, A., Azam, F., Selwi, W., Gharaibeh, L., Alatawi, Y., Alruwaii, Z., & Alsaab, H. O. (2023). PD-L1 is highly expressed in ovarian cancer and associated with cancer stem cells populations expressing CD44 and other stem cell markers. BMC Cancer, 23(1), 13. Citations: 41

  6. Alessy, S. A., Almotlak, A. A., Alattas, M., Alshareef, A., Alwosaibai, K., Alghamdi, M. A., Razack, H. I. A., & Alqahtani, S. A. (2024). Cancer research challenges and potential solutions in Saudi Arabia: A qualitative discussion group study. JCO Global Oncology, 10, e2300189. Citations: 18

  7. Alwosaibai, K., Alruwaii, Z. I., Mashhour, M., Almsned, F. M., Asraf, R., Alrsheedy, W., Alessa, A., Almohanna, H., Selwi, W., & Azam, F. (2024). Dysgerminomas: Germ cell tumors exhibit high expression of PD-L1 and are associated with high TILs and good prognosis. Scientific Reports, 14(1), 24191. Citations: 12

 

Radoslaw Kazmierski | Medical Hypotheses | Medical Hypothesis Award

Published on by Research Hypothesis

Prof. Dr. Radoslaw Kazmierski | Medical Hypotheses | Medical Hypothesis Award

Professor, University of Zielona Gora, Poland

Prof. Dr. Radoslaw Kazmierski is a distinguished researcher whose expertise lies in neurology, stroke medicine, and cerebrovascular disorders. He has contributed significantly to advancing knowledge in stroke prevention, diagnosis, and treatment through his clinical and translational research. He holds a Ph.D. in medicine with specialization in neurological sciences, which has shaped his academic and research pursuits. Prof. Dr. Radoslaw Kazmierski has actively collaborated on international research projects focusing on stroke risk stratification and cognitive impairment, bringing a global perspective to his work. He has authored 49 documents, accumulating 781 citations with an h-index of 14, demonstrating the academic impact and relevance of his research within the medical community. His publication portfolio includes papers in reputed journals indexed in Scopus and other high-impact platforms, making a substantial contribution to evidence-based medicine. Prof. Dr. Radoslaw Kazmierski has also engaged in leadership roles within academic and clinical research settings, mentoring young researchers and guiding clinical trials. He has been associated with professional memberships in neurology associations and continues to contribute to advancing stroke awareness and patient care standards. His work bridges academia, clinical application, and community health initiatives, making him a valuable contributor to global neurological research.

Profile:  Scopus | ORCID

Featured Publications

  1. Short-term outcome after ischemic stroke and 24-h blood pressure variability: association and predictors — 2021; cited by multiple studies as a key predictor model.

  2. Serum Paraoxonase/Arylesterase Activity Affects Outcome in Ischemic Stroke Patients — 2011; widely cited in studies of redox biomarkers and stroke prognosis.

  3. Zaburzenia mowy i języka u pacjentów po przebytym udarze mózgu. Studium epidemiologiczne — 2022; epidemiological study of speech and language disorders post-stroke; though newer, it contributes to functional outcomes research.

Xiaodan Zhang | Medicine and Health Sciences | Best Researcher Award Medicine and Health Sciences

Published on by Research Hypothesis

Assoc. Prof. Dr. Xiaodan Zhang | Medicine and Health Sciences | Best Researcher Award

Medicine and Health Sciences College of Life and Science Zhejiang Sci-Tech University, China      

Dr. Xiaodan Zhang is an accomplished Associate Professor at the College of Life Science and Medicine, with a Ph.D. in Pharmacy from Chung-Ang University (2013). With over a decade of academic and research experience, she has made significant contributions to the fields of pharmacognosy, natural product chemistry, and metabolomics. Her research focuses on the spatial distribution and pharmacological properties of bioactive compounds using advanced techniques like UPLC-Q-TOF-MS and DESI-MSI. Dr. Zhang has published extensively in high-impact journals such as Horticulture Research, Food Chemistry, and Molecules, often serving as corresponding author. Her work is characterized by a strong interdisciplinary approach, combining omics technologies and mass spectrometry to uncover therapeutic potentials of traditional medicinal plants. Despite limited mention of major awards or grants, her consistent publication record, scientific rigor, and collaborative projects establish her as a highly credible and forward-thinking researcher in the biomedical sciences.

Professional Profile 

🎓 Education Background of Dr. Xiaodan Zhang

Dr. Xiaodan Zhang holds a distinguished academic background in the field of Pharmacy. She earned her Doctor of Philosophy (Ph.D.) in Pharmacy in 2013 from Chung-Ang University, South Korea—an institution recognized for its excellence in pharmaceutical sciences and biomedical research. Her doctoral studies laid the foundation for her future work in natural product pharmacology and metabolomics, equipping her with advanced knowledge in analytical chemistry, drug discovery, and plant-based therapeutic research. Her academic journey reflects a strong commitment to scientific inquiry and innovation.

💼 Professional Experience of Dr. Xiaodan Zhang

Dr. Xiaodan Zhang has over a decade of dedicated academic and research experience in the biomedical sciences. She began her professional journey as an Assistant Professor at the College of Life Science and Medicine in 2013, a role she held for five years. In 2019, she was promoted to the position of Associate Professor, reflecting her growing leadership and contributions in research and teaching. Over these ten years, Dr. Zhang has been actively involved in advanced pharmacological studies, curriculum development, and interdisciplinary research collaborations. Her experience underscores a strong progression in academic ranks and a sustained commitment to excellence in the fields of pharmacy, life sciences, and medicinal chemistry.

🔬 Research Interests of Dr. Xiaodan Zhang

Dr. Xiaodan Zhang’s research interests lie at the intersection of natural product pharmacology, metabolomics, and multi-omics integration. She is particularly focused on exploring the chemical composition, spatial distribution, and pharmacological activity of traditional medicinal plants using advanced analytical tools such as UPLC-Q-TOF-MS, DESI-MSI, and network pharmacology. Her work aims to identify bioactive compounds with anti-cancer, anti-inflammatory, antioxidant, and neuroprotective properties. By combining spectrum-effect relationships with high-resolution mass spectrometry, Dr. Zhang contributes to the scientific validation and modernization of herbal medicines. Her research not only advances fundamental knowledge in pharmaceutical sciences but also supports the development of safer and more effective therapeutic agents from natural sources.

🏅 Awards and Honors of Dr. Xiaodan Zhang

Dr. Xiaodan Zhang has earned recognition for her dedicated contributions to the fields of pharmacy, metabolomics, and traditional medicine research. While specific awards and honors are not detailed in her current CV, her consistent authorship in high-impact journals such as Horticulture Research, Food Chemistry, and Molecules reflects a high level of academic distinction and peer recognition. Her role as a corresponding author on multiple publications and her advancement to Associate Professor further underscore the esteem she holds within the scientific community. As her research continues to gain traction globally, Dr. Zhang is well-positioned for future honors and prestigious research accolades in the biomedical and pharmaceutical sciences.

🏁 Conclusion

Dr. Xiaodan Zhang demonstrates strong suitability for the Best Researcher Award in Pharmacy or Life Sciences. Her profile reflects a high-caliber researcher with solid academic credentials, prolific publication output in impactful journals, and an evident commitment to advancing research in natural product pharmacology and metabolomics.

📚 Publications Top Note

  1. Title: Alternaria alstroemeriae F1 inhibits Aspergillus flavus growth and weakens aflatoxins biosynthesis
    Authors: [Not fully listed in your input]
    Journal: Fungal Genetics and Biology
    Year: 2025
    Citations: 0

  2. Title: Medicinal and edible homologous poly/oligo-saccharides: Structural features, effect on intestinal flora and preventing and treating type 2 diabetes, and their applications: A review
    Authors: [Not fully listed in your input]
    Type: Review Article
    Year: 2025
    Citations: 0

  3. Title: Directed evolution of diacylglycerol acyltransferases 2 promotes lipids and triglyceride accumulation
    Authors: [Not fully listed in your input]
    Journal: Plant Molecular Biology
    Year: 2025
    Citations: 0

  4. Title: Exploring the Metabolic and Transcriptomic Profiles of Tetrastigma hemsleyanum for Tissue-Specific Compound Accumulation
    Authors: [Not fully listed in your input]
    Journal: Frontiers in Plant Science
    Year: 2025
    Open Access: 
    Citations: 0

  5. Title: Analysis of the correlation between the distribution of microorganisms carried by Coix seed and fungal toxins, and the biological control of aflatoxin
    Authors: [Not fully listed in your input]
    Journal: Current Research in Food Science
    Year: 2025
    Open Access: 
    Citations: 0